News

Precision Therapeutics plans to launch new genomics product next year

Fresh off a $34 million Series D fundraise, Precision Therapeutics Inc. is planning to launch a “genomics” product sometime in 2011. CEO Sean McDonald offered few details beyond that, however. “All of our technology is geared toward helping patients and doctors understand which treatments are likely to be most effective based on [the cancer patient’s] […]

Fresh off a $34 million Series D fundraise, Precision Therapeutics Inc. is planning to launch a “genomics” product sometime in 2011.

CEO Sean McDonald offered few details beyond that, however. “All of our technology is geared toward helping patients and doctors understand which treatments are likely to be most effective based on [the cancer patient’s] genetics and the tumor’s characteristics” and the new product will be no different in that respect, McDonald said. Genomics refers to the study of the entire set of DNA instructions that makes up an organism.

The company currently has one product on the market, a test called ChemoFX, which registered $23 million in sales last year, nearly triple the prior year. Precision Therapeutics hopes to capitalize on the growing personalized medicine trend that advocates say will help cut health costs and boost the effectiveness of treatments by ruling out drugs that are shown not to help certain patients.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

McDonald admitted that the company’s latest fundraise was essentially a Plan C after Precision Therapeutics first scrapped IPO then merger plans in recent years, blaming the weak economy in each instance. “Our business has continued to do well. The public markets have not continued to do well,” said McDonald.

“We believe this is the preferred scenario to grow our business going forward,” he said, noting that the company isn’t worried about an exit for the time being.

The latest commitment brings the funding that the company has raised since its 1995 inception to more than $100 million, McDonald said. Last year, Precision Therapeutics was named the 64th fastest-growing privately held healthcare company in the U.S. by Inc. Magazine.